Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Mosley Wealth Management

Mosley Wealth Management increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,151 shares of the medical research company’s stock after buying an additional 73 shares during the period. Mosley Wealth Management’s holdings in Amgen were worth $360,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Horizon Financial Services LLC acquired a new position in Amgen in the first quarter valued at approximately $28,000. United Community Bank purchased a new stake in Amgen in the fourth quarter valued at $29,000. nVerses Capital LLC purchased a new stake in Amgen in the second quarter valued at $31,000. Bbjs Financial Advisors LLC acquired a new position in Amgen in the second quarter valued at $33,000. Finally, Western Pacific Wealth Management LP purchased a new position in shares of Amgen during the fourth quarter worth about $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several research reports. Oppenheimer reissued an “outperform” rating and issued a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Bank of America lifted their target price on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Royal Bank of Canada upped their price target on shares of Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Finally, Argus raised their price objective on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Eleven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $327.28.

Amgen Stock Performance

NASDAQ AMGN traded down $3.80 on Friday, hitting $320.56. 2,242,451 shares of the company’s stock were exchanged, compared to its average volume of 2,541,291. The firm has a market cap of $171.96 billion, a price-to-earnings ratio of 45.79, a P/E/G ratio of 2.96 and a beta of 0.58. The firm’s 50-day moving average price is $326.26 and its two-hundred day moving average price is $302.12. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s revenue was up 20.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.00 EPS. On average, research analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.81%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.